Key Metrics

Market Cap
Total Shares Outstanding
Book Value
PE Ratio

PS Ratio
PB Ratio
Forward PE Ratio
ROIC

Return on Aseets
Return on Equity
Dividend
Dividend Yield

Balancesheet Metrics

Total Assets	3.07M
Total Liability	7.29M
Assets-to-Libability Ratio	0.42

Total Current Assets	2.63M
Total Current Liability	2.93M
Current Ratio	0.9

Quick Ratio	0.93
Debt to Equity Ratio	-

Income Statement Metrics

Net Income
EPS
EBITA

Gross Profit
Gross Profit Margin
Operating Margin

Net Profit Margin

Price Metrics

5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA

52 Weeks High
52 Weeks low
All Time High

RSI
MACD

Share Stats

Shares Float
Shares Short

% Short
% Insider

% Institutions

% Institutions

News

Profile

Comera Life Sciences Holdings Inc (CMRAW)

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Exchange: NASDAQ

IPO Date: 5/20/2022

Sector: Healthcare

Industry: Biotechnology

Employees: 12

Address: 12 Gill Street, Woburn, MA, United States, 01801

https://comeralifesciences.com

Quarterly Yearly

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	Totals
	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	Totals
Assets	3.07K	2.34K	3.00K	3.73K	4.94K	6.13K	4.96K	-	28.17K
Current Assets	2.63K	1.82K	2.41K	3.06K	4.29K	5.41K	4.38K	-	24.00K
Cash And Short Term Investments	1.77K	476.302	1.54K	446.607	2.67K	4.94K	3.86K	-	15.70K
Net Receivables	100	250	248.635	34.32	293.821	148.998	148.165	-	1.22K
Inventory	-100	1.04K	535.098	2.51K	1.27K	-	-	-	5.26K
Other Current Assets	862.626	58.845	85.051	72.888	51.49	31.257	6.19	-	1.17K
Non Current Assets	441.453	516.138	591.68	664.015	648.191	719.818	582.749	-	4.16K
Non Currrent Assets Other	93.2	93.2	93.2	93.2	93.2	93.2	82.2	-	641.4000000000001
Liabilities	7.29K	8.69K	8.26K	9.97K	8.37K	7.92K	22.05K	22.10K	94.67K
Current Liabilities	2.93K	3.95K	3.36K	5.06K	3.43K	2.52K	1.03K	1.05K	23.33K
Accounts Payable	1.14K	2.15K	1.77K	1.46K	1.44K	1.43K	631.477	416.941	10.44K
Short Long Term Debt	-	584.809	-	455.562	911.124	-	-	-	1.95K
Other Current Liabilities	389.872	959.773	1.37K	2.80K	887.012	906.777	224.07	7.91	7.54K
Non Current Liabilities	4.36K	4.74K	4.91K	4.92K	4.94K	5.40K	21.03K	-	50.28K
Stockholder Equity	-4.22K	-6.35K	-5.26K	-6.25K	-3.43K	-1.79K	-17.09K	-14.69K	-59.08K
Liabilities And Stockholders Equity	3.07K	2.34K	3.00K	3.73K	4.94K	6.13K	4.96K	-	28.17K
Totals		23.84K	23.66K	25.90K	32.75K	35.73K	39.99K	46.85K	8.89K	237.62K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2022	12/31/2021	12/31/2020	Totals
	12/31/2022	12/31/2021	12/31/2020	Totals
Assets	3.73K	7.42K	545.878	11.69K
Current Assets	3.06K	6.78K	310.388	10.15K
Cash And Short Term Investments	446.607	6.51K	155.427	7.11K
Net Receivables	34.32	221.554	115.268	371.142
Inventory	2.51K	2	21.923	2.53K
Other Current Assets	72.888	47.38	17.77	138.038
Non Current Assets	664.015	636.74	235.49	1.54K
Non Currrent Assets Other	93.2	82.2	57.2	232.60000000000002
Liabilities	9.97K	22.10K	393.963	32.47K
Current Liabilities	5.06K	1.05K	233.375	6.34K
Accounts Payable	1.46K	416.941	97.616	1.97K
Short Long Term Debt	455.562	-	-	455.562
Other Current Liabilities	2.80K	7.91	1.394	2.81K
Non Current Liabilities	4.92K	21.06K	160.588	26.14K
Stockholder Equity	-6.25K	-14.69K	151.915	-20.78K
Liabilities And Stockholders Equity	3.73K	7.42K	545.878	11.69K
Totals		32.75K	59.06K	3.04K	94.86K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	06/30/2022	03/31/2022	06/30/2021	Totals
	06/30/2022	03/31/2022	06/30/2021	Totals
Revenue	146.726	95.334	70.917	312.977
Cost Of Revenue	54.543	44.524	57.567	156.63400000000001
Gross Profit	92.183	50.81	13.35	156.343
Operating Expenses	4.12K	2.55K	1.97K	8.64K
Selling General Administrative	3.70K	2.02K	1.24K	6.95K
Research Development	368.553	487.217	679.635	1.54K
Other Operating Expenses	-	-	-	-
Operating Income	-3.97K	-2.45K	-1.90K	-8.33K
Net Interest Income	-	-0.077	-	-0.077
Interest Income	-	-	-	-
Interest Expense	-	0.077	-	0.077
Other Income Expense Net	-5.11K	-426.666	-76.738	-5.62K
Income Before Tax	-9.09K	-2.88K	-1.98K	-13.95K
Tax Provision	-	-	-	-
NetIncome	-9.09K	-2.88K	-1.98K	-13.95K
NetIncome Applicable To Common Shares	-	-	-	-
Ebit	-	-	-	-
Totals		-18.78K	-3.40K	-1.91K	-24.08K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2021	12/31/2020	Totals
	12/31/2021	12/31/2020	Totals
Revenue	319.832	442.919	762.751
Cost Of Revenue	161.008	104.407	265.415
Gross Profit	158.824	338.512	497.336
Operating Expenses	5.86K	2.57K	8.43K
Selling General Administrative	3.94K	1.20K	5.15K
Research Development	1.75K	1.26K	3.01K
Other Operating Expenses	-	-	-
Operating Income	-5.54K	-2.13K	-7.66K
Net Interest Income	-	-	-
Interest Income	-	-	-
Interest Expense	-	-	-
Other Income Expense Net	83.85	2.033	85.883
Income Before Tax	-5.45K	-2.13K	-7.58K
Tax Provision	-	-	-
NetIncome	-5.45K	-2.13K	-7.58K
NetIncome Applicable To Common Shares	-	-	-
Ebit	-	-	-
Totals		-4.17K	-454.15200000000004	-4.62K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	06/30/2021	Totals
	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	12/31/2021	06/30/2021	Totals
Cash From Operating Activities	-1.91K	-993.503	-1.91K	-1.85K	-2.39K	-2.67K	-2.87K	-3.76K	-	-18.34K
Net Income	-2.15K	-1.41K	-2.48K	-2.96K	-3.08K	-9.09K	-2.88K	-5.45K	-1.98K	-31.48K
Depreciation	22.994	24.844	28.26	23.763	23.79	21.62	24.774	86.136	-	256.18100000000004
Extraordinary Items	-	-	-	-	-	-	-	-	-	-
Change To Inventory	476.449	38.303	-	-	-	-	-	-	-	514.752
Capital Expenditures	-	-5.65	-88.359	-28.58K	-25.154	-3.453	-	-142.013	-	-28.85K
Cash From Financing Activities	3.21K	-63.198	1.58K	1.13K	145.162	3.74K	222.513	10.28K	-	20.25K
Sale Purchase Of Stock	-	-0.208	-	650.00K	748.888	-	-	-	-	650.75K
Other Cashflows From Financing Activities	3.21K	-62.99	1.53K	-648.95K	145.162	3.74K	222.513	10.28K	-	-629.88K
Totals		2.84K	-2.47K	-1.34K	-31.19K	-4.43K	-4.24K	-5.28K	11.29K	-1.98K	-36.79K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2023	12/31/2022	12/31/2021	12/31/2020	Totals
	12/31/2023	12/31/2022	12/31/2021	12/31/2020	Totals
Cash From Operating Activities	-6.66K	-9.77K	-3.76K	-1.80K	-21.99K
Net Income	-9.01K	-18.00K	-5.45K	-2.13K	-34.59K
Depreciation	99.861	93.947	86.136	89.749	369.693
Extraordinary Items	-	-	-	-	-
Change To Inventory	-	-	173.96	76.24	250.2
Capital Expenditures	-94.009	-28.607	-142.013	-12.366	-276.995
Cash From Financing Activities	5.85K	5.24K	10.28K	1.55K	22.93K
Sale Purchase Of Stock	-	650.00K	-	-	650.00K
Other Cashflows From Financing Activities	-	-645.59K	10.28K	160.588	-635.15K
Totals		-9.81K	-18.06K	11.47K	-2.06K	-18.46K

Profile

Free Stocks

Company

Features

Contact Us